Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

Efficient Inhibition of Uveal Melanoma via Ternary siRNA Complexes
Publication date: Available online 23 November 2019Source: International Journal of PharmaceuticsAuthor(s): Lingxiao Xie, Yan Yang, Jie ShenAbstractUveal melanoma (UM) is rare yet the most common and malignant primary intraocular tumor in adults. Due to the lack of effective treatment, the mortality rate of UM has remained high over the past few decades. In the present study, hyaluronic acid (HA) coated chitosan (Chi)/siRNA ternary complexes have been developed and characterized as a novel therapeutic strategy molecularly targeting hypoxia-inducible factor 1α (HIF-1α) pathway for the treatment of UM. The cytotoxicity, ce...
Source: International Journal of Pharmaceutics - November 23, 2019 Category: Drugs & Pharmacology Source Type: research

Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines
ConclusionsThis study yielded effective siRNA carriers for combinational delivery of siRNAs. Careful choice of siRNA combinations will be critical since targeting individual genes might alter the expression of other critical mediators.
Source: Pharmaceutical Research - February 2, 2020 Category: Drugs & Pharmacology Source Type: research

The effects of fluoroalkyl chain length and density on siRNA delivery of bioreducible poly(amido amine)s.
Abstract Fluorination is an attractive strategy for the improvement of transfection efficiency of nucleic acid delivery vectors. Bioreducible poly(amido amine)s (bPAAs) are an important class of biomaterials exhibited to effectively deliver multiple nucleic acids. However, still, the effects of fluoroalkyl chain length and density of bPAA on siRNA delivery are unveiled. Here, we synthesized bPAAs and grafted with different chain lengths and densities of fluorocarbon compounds. Furthermore, we prepared a library of complexes of fluorinated bPAA and siRNA, and investigated the effects of fluorination on the siRNA de...
Source: European Journal of Pharmaceutical Sciences - June 22, 2020 Category: Drugs & Pharmacology Authors: Chen G, Wang Y, Ullah A, Huai Y, Xu Y Tags: Eur J Pharm Sci Source Type: research

Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
In this study, novel nanoparticles (PTX/siRNA/FALS) were constructed by using tripeptide lipid (L), sucrose laurate (S), and folate-PEG2000-DSPE (FA) to co-deliver PTX and siRNA. The cancer cell targeting nanoparticle carrier (PTX/siRNA/FALS) showed anticipated PTX encapsulation efficiency, siRNA retardation ability, improved cell uptake and sustained and controlled drug release. It led to significant anti-tumor activity in vitro and in vivo by efficient inhibition of VEGF expression and induction of cancer cell apoptosis. Importantly, the biocompatibility of the carriers and low dosage of PTX required for effective ther...
Source: Drug Delivery - October 26, 2020 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA.
In conclusion, PBA-modified COSs can serve as a promising carrier for siRNA delivery in the field of anti-tumor therapy. PMID: 33220463 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - November 18, 2020 Category: Drugs & Pharmacology Authors: Liu X, Chen L, Zhang Y, Xin X, Qi L, Jin M, Guan Y, Gao Z, Huang W Tags: Eur J Pharm Sci Source Type: research

siRNA delivery to macrophages using aspherical, nanostructured microparticles as delivery system for pulmonary administration.
Abstract The delivery of oligonucleotides such as siRNA to the lung is a major challenge, as this group of drugs has difficulties to overcome biological barriers due to its polyanionic character and the associated hydrophilic properties, resulting in inefficient delivery. Especially in diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis, where increased proinflammation is present, a targeted RNA therapy is desirable due to the high potency of these oligonucleotides. To address these problems and to ensure efficient uptake of siRNA in macrophages, a microparticulate, cylindrical deliv...
Source: European Journal of Pharmaceutics and Biopharmaceutics - December 4, 2020 Category: Drugs & Pharmacology Authors: Fischer T, Tschernig T, Drews F, Brix K, Meier C, Simon M, Kautenburger R, Schneider M Tags: Eur J Pharm Biopharm Source Type: research

The growth of siRNA-based therapeutics: updated clinical studies.
Abstract More than two decades after the natural gene-silencing mechanism of RNA interference was elucidated, small interfering RNA (siRNA)-based therapeutics have finally broken into the pharmaceutical market. With three agents already approved and many others in advanced stages of the drug development pipeline, siRNA drugs are on their way to becoming a standard modality of pharmacotherapy. The majority of late-stage candidates are indicated for rare or orphan diseases, whose patients have an urgent need for novel and effective therapies. Additionally, there are agents that have the potential to meet the need of...
Source: Biochemical Pharmacology - January 26, 2021 Category: Drugs & Pharmacology Authors: Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB Tags: Biochem Pharmacol Source Type: research

siRNA Therapeutics: Future Promise for Neurodegenerative Diseases
Curr Neuropharmacol. 2021 Apr 1. doi: 10.2174/1570159X19666210402104054. Online ahead of print.ABSTRACTNeurodegenerative diseases (ND), as a group of central nervous system (CNS) disorders, are among the most prominent medical problems in the 21st century. They are often associated with considerable disability, motor dysfunction and dementia and are more common in the aged population. ND imposes a psychologic, economic and social burden on the patients and their families. Currently, there is no effective treatment for ND. Since many of ND results from the gain of function of a mutant allele, small interference RNA (siRNA) ...
Source: Current Neuropharmacology - April 2, 2021 Category: Drugs & Pharmacology Authors: Atefeh Amiri George Barreto Thozhukat Sathyapalan Amirhossein Sahebkar Source Type: research

Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis
In this study, we investigated the effects of siRNA delivered using MPEG-PCL-CH2R4H2C nanomicelles through intravenous administration to the inflammation site of dextran sulfate sodium-induced colitis mice. The MPEG-PCL-CH2R4H2C micelles had optimum physical properties and high siRNA compaction ability. Moreover, model-siRNA delivered through MPEG-PCL-CH2R4H2C showed higher accumulation in the inflammatory site than that of the naked siRNA. Furthermore, intravenous administration of MPEG-PCL-CH2R4H2C/siRelA micelles, targeting siRelA, a subunit of NF-κB, significantly decreased the shortening of large intestine, clinical ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - December 29, 2021 Category: Drugs & Pharmacology Authors: Hisako Ibaraki Naruhiro Hatakeyama Naoki Arima Akihiro Takeda Yasuo Seta Takanori Kanazawa Source Type: research

Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA
In this study, we demonstrated a novel strategy to construct negatively charged and ultrasound (US)-responsive O-carboxymethyl chitosan (O-CMS) NDs as a siRNA targeted delivery system through three-way junction of bacteriophage phi29 DNA packaging motor (3WJ-pRNA) nanotechnology. 39nt A10-3.2 aptamer targeting prostate specific membrane antigen (PSMA) and 21nt siRNA against cationic amino acid transporter 1 (siCAT-1) were annealed to 3WJ-pRNA scaffold via complementation with an extended sequence. The cholesterol molecule attached to one branch facilitates the 3WJ-pRNA nanoparticles anchoring onto NDs. The desired O-CMS ND...
Source: Drug Delivery - January 17, 2022 Category: Drugs & Pharmacology Authors: Lu Guo Dandan Shi Mengmeng Shang Xiao Sun Dong Meng Xinxin Liu Xiaoying Zhou Jie Li Source Type: research